Benchmark Co. Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $40
Analysts Are Bullish on Top Healthcare Stocks: Surgery Partners (SGRY), Liquidia Technologies (LQDA)
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $28
BofA Securities Initiates Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $30
Surgery Partners Reinstated With a Buy at BofA
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
Key Takeaways From Surgery Partners Analyst Ratings
Surgery Partners Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $35
Surgery Partners Is Maintained at Outperform by Macquarie
Surgery Partners Price Target Maintained With a $34.00/Share by Macquarie
Macquarie Maintains Surgery Partners(SGRY.US) With Buy Rating
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $32
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $40
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $31 to $50
Surgery Partners Analyst Ratings
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating
Strong Q3 Performance and Strategic Growth Bolster 'Buy' Rating for Surgery Partners
Surgery Partners Price Target Maintained With a $35.00/Share by Macquarie
Surgery Partners Analyst Ratings